Extended Data Fig. 5: The capecitabine/5-FU mutational footprint.

a, Association between a mutational signature and the treatment with capecitabine and/or 5-FU. The numbers in the table represent the p-value and effect size of the corresponding regression models testing the effect of both drugs separate or pooling the tumors exposed to either. The association between the signature and 5-FU treatment does not reach significance (p=0.07), but exhibits a large effect size. b, Contribution of capecitabine and 5-FU to the mutation burden of colorectal (left) or breast (right) tumors exposed to either drug. The barplots represent the proportion of 5-FU- and capecitabine-exposed tumors with activity of the SBS Capecitabine/5-FU signature. c, Mutational profile of 5-FU-induced mutations in five resistant strains of Leishmania infantum. The profile was built with the mutations private to the strains after treatment with 5-FU (that is, after subtraction of the mutations found in the parental strain). d, Contribution of SBS Capecitabine/5-FU signature and the previously reported 17b signature (Sig17b) to the mutation burden of colorectal and breast tumors either not exposed or exposed to capecitabine/5-FU.